Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Real-world data of TAS-102 therapy in refractory metastatic colorectal cancer (mCRC): The experience of the University Hospital of Montreal (CHUM).
Authors
Reem El Khoury
Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC, Canada
Reem El Khoury , Jad Tehfe , Marie Ouellet , Francine Aubin , Rasmy Lougnarath , Jean-Pierre M. Ayoub , Mustapha Tehfe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 137)
DOI
10.1200/JCO.2024.42.3_suppl.137
Abstract #
137
Poster Bd #
J3
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Impact of KRAS codon-specific mutations on survival of patients with metastatic CRC (mCRC) treated with trifluridine-tipiracil (TAS) plus bevacizumab (Bev): A real-world analysis.
First Author: Giulia Maddalena
Poster
2016 Gastrointestinal Cancers Symposium
TAS-102 versus placebo plus best supportive care in patients with metastatic colorectal cancer refractory to standard therapies: Final survival results of the phase 3 RECOURSE trial.
First Author: Robert J. Mayer
Poster
2023 ASCO Annual Meeting
Association of adaptive immunity/inflammatory genes with survival in prostate cancer.
First Author: Austin Hopper
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Prognostic indicators of KRAS G12X mutations in pancreatic cancer.
First Author: Bach Ardalan